Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease

被引：0
|
作者：
Emily Chan
Eunice L. Kwak
Jimmy Hwang
Marja Heiskala
Guillaume de La Bourdonnaye
Monica Mita
机构：
[1] Vanderbilt-Ingram Cancer Center,Division of Hematology/Oncology
[2] Massachusetts General Hospital,Institute for Drug Development
[3] Georgetown University Hospital,Samuel Oschin Comprehensive Cancer Institute
[4] Merck KGaA,undefined
[5] Cancer Therapy and Research Center UTHSCSA,undefined
[6] Philip Morris International,undefined
[7] Cedars-Sinai Medical Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Cetuximab; Colorectal cancer (CRC); FOLFIRI; IMO-2055 (EMD 1201081); Toll-like receptor 9 agonist (TLR9);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：701 / 709
页数：8
相关论文
共 30 条
  • [1] Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
    Chan, Emily
    Kwak, Eunice L.
    Hwang, Jimmy
    Heiskala, Marja
    de La Bourdonnaye, Guillaume
    Mita, Monica
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 701 - 709
  • [2] Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy
    Souglakos, J.
    Kalykaki, A.
    Vamvakas, L.
    Androulakis, N.
    Kalbakis, K.
    Agelaki, S.
    Vardakis, N.
    Tzardi, M.
    Kotsakis, A. P.
    Gioulbasanis, J.
    Tsetis, D.
    Sfakiotaki, G.
    Chatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 305 - 310
  • [3] Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
    Shah, Manish A.
    Yoshino, Takayuki
    Tebbutt, Niall C.
    Grothey, Axel
    Tabernero, Josep
    Xu, Rui-Hua
    Cervantes, Andres
    Oh, Sang Cheul
    Yamaguchi, Kensei
    Fakih, Marwan
    Falcone, Alfredo
    Wu, Christina
    Chiu, Vi K.
    Tomasek, Jiri
    Bendell, Johanna
    Fontaine, Marilyn
    Hitron, Matthew
    Xu, Bo
    Taieb, Julien
    Van Cutsem, Eric
    CLINICAL COLORECTAL CANCER, 2023, 22 (01) : 100 - 110
  • [4] Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial
    Sadahiro, Sotaro
    Suzuki, Toshiyuki
    Okada, Kazutake
    Saito, Gota
    Miyakita, Hiroshi
    Ogimi, Takashi
    Chan, Lin Fung
    Kamei, Yutaro
    ONCOLOGY, 2020, 98 (09) : 637 - 642
  • [5] FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
    Cremolini, Chiara
    Loupakis, Fotios
    Antoniotti, Carlotta
    Lupi, Cristiana
    Sensi, Elisa
    Lonardi, Sara
    Mezi, Silvia
    Tomasello, Gianluca
    Ronzoni, Monica
    Zaniboni, Alberto
    Tonini, Giuseppe
    Carlomagno, Chiara
    Allegrini, Giacomo
    Chiara, Silvana
    D'Amico, Mauro
    Granetto, Cristina
    Cazzaniga, Marina
    Boni, Luca
    Fontanini, Gabriella
    Falcone, Alfredo
    LANCET ONCOLOGY, 2015, 16 (13) : 1306 - 1315
  • [6] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Hong, Yong Sang
    Lee, Jeeyun
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Park, Young Suk
    Park, Joon Oh
    Park, Se Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Kim, Tae-You
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 183 - 191
  • [7] Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial
    Wang, Zhan
    Qin, Bao-Dong
    Ye, Chen-Yang
    Wang, Miao-Miao
    Yuan, Ling-Yan
    Dai, Wei-Ping
    Sun, Li
    Liu, Ke
    Qin, Wen-Xing
    Jiao, Xiao-Dong
    Li, Xing-Nan
    Zang, Yuan-Sheng
    EUROPEAN JOURNAL OF CANCER, 2022, 163 : 152 - 162
  • [8] A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan
    Fora, Ahmad A.
    McMahon, Jeanne A.
    Wilding, Greg
    Groman, Adrienne
    Ma, Wen Wee
    Romano, Karen S.
    Fakih, Marwan G.
    ONCOLOGY, 2013, 84 (04) : 210 - 213
  • [9] A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment
    Jean-Pierre Delord
    Guillem Argilés
    Jerôme Fayette
    Lori Wirth
    Stefan Kasper
    Salvatore Siena
    Ricard Mesia
    Rossana Berardi
    Andrés Cervantes
    Jeroen Dekervel
    Sylvia Zhao
    Yongjian Sun
    Huai-Xiang Hao
    Ralph Tiedt
    Sergio Vicente
    Andrea Myers
    Lillian L. Siu
    Investigational New Drugs, 2020, 38 : 1774 - 1783
  • [10] A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment
    Delord, Jean-Pierre
    Argiles, Guillem
    Fayette, Jerome
    Wirth, Lori
    Kasper, Stefan
    Siena, Salvatore
    Mesia, Ricard
    Berardi, Rossana
    Cervantes, Andres
    Dekervel, Jeroen
    Zhao, Sylvia
    Sun, Yongjian
    Hao, Huai-Xiang
    Tiedt, Ralph
    Vicente, Sergio
    Myers, Andrea
    Siu, Lillian L.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1774 - 1783
123